peptide-drug conjugates a single molecule that can simultaneously play multiple roles in a drug delivery system - Peptide--drugconjugatesreview have emerged as promising precision medicine tools Peptide-Drug Conjugates: Revolutionizing Targeted Therapeutics

Research advances inpeptide drug conjugates Peptide-drug conjugates (PDCs) are rapidly emerging as a groundbreaking class of therapeutics, promising enhanced efficacy and reduced toxicity in treating a wide range of diseases, particularly cancer. These innovative drug conjugates represent the next generation of targeted therapies, building upon the success of antibody-drug conjugates (ADCs) but offering distinct advantages作者：D Wang·2025·被引用次数：30—Similar to ADCs, peptide-drug conjugates (PDCs) are defined asdrugs covalently linked to peptideswith certain functions via specialized .... The core concept behind peptide-drug conjugates involves the strategic combination of a targeting peptide with a potent drug molecule, linked together by a specialized linker. This sophisticated molecular architecture allows for the precise delivery of therapeutic agents directly to diseased cells, minimizing collateral damage to healthy tissues.Conjugation with peptides helps to overcome their inherent drawbackssuch as poor solubility, short half-life, drug resistance, and system toxicity, by ...

The development of peptide-drug conjugates is driven by the need for more sophisticated and effective treatment modalities. As highlighted in numerous recent publications, PDCs have emerged as a next-generation therapeutic platform. This platform leverages the inherent specificity of peptides for certain cellular targets, such as overexpressed receptors on cancer cells, to guide the attached cytotoxic payloadA Brief Guide to Preparing a Peptide–Drug Conjugate - 2023. Unlike larger antibodies used in ADCs, peptides offer superior tissue penetration and smaller size, allowing them to access tumor microenvironments more effectively. Furthermore, the easier chemical synthesis and lower production costs associated with peptides make PDCs a more accessible and scalable therapeutic option.

A key structural component of peptide-drug conjugates is the linker.Peptide-Drug Conjugates (PDCs) | 多肽偶联药物 The linker between the drug and the peptide plays a critical role in the stability and release profile of the conjugates, influencing how effectively the drug is delivered and activated at the target site. Researchers are actively exploring various linker chemistries to optimize drug release kinetics and ensure payload stability during circulation. The endeavor of determining the finest conjugation reaction is paramount to successful PDC development.

The therapeutic potential of peptide-drug conjugates is vast. They have emerged as promising precision medicine tools due to their ability to combine the targeting precision of peptides with the potent killing power of small molecule drugs or cytotoxic agents. This synergy allows for the development of therapeutic compounds that combine peptides with drug molecules, enhancing targeted delivery and efficacy. For instance, in oncology, PDCs can be designed to target specific cancer cell surface receptors, delivering a potent chemotherapy agent directly to the tumor. This targeted approach not only improves treatment outcomes but also helps to overcome inherent drawbacks such as poor solubility, short half-life, drug resistance, and systemic toxicity often associated with conventional chemotherapy.作者：M Alas·2020·被引用次数：256—Drug conjugates are chemotherapeutic or cytotoxic agentscovalently linked to targeting ligands such as an antibody or a peptide via a ...

The global peptide drug conjugates market size accounted for USD 3,733 million in 2024 and is projected to experience significant growth, reaching approximately USD 21,800 million by 2034. This burgeoning market reflects the increasing recognition of PDCs' therapeutic value and the ongoing research and development in this field. Research advances in peptide drug conjugates are continually expanding their applications beyond cancer, with potential uses in treating inflammatory diseases, autoimmune disorders, and infectious diseases.Peptide-Drug Conjugates- A Novel Approach to Drug Design

The construction of a peptide-drug conjugate involves three main elements: a cytotoxic agent (or payload), a homing peptide, and a linker. Some PDCs are even designed as a single molecule that can simultaneously play multiple roles in a drug delivery system, encompassing in vivo drug distribution and targeted release.作者：D Wang·2025·被引用次数：30—Similar to ADCs, peptide-drug conjugates (PDCs) are defined asdrugs covalently linked to peptideswith certain functions via specialized ... The peptides commonly used in PDCs are typically small, ranging from 5 to 30 amino acid residues, and are selected for their high affinity and specificity for particular cellular targets.Peptide-Drug Conjugates (PDCs): Development Status & ... These peptides act as the guiding mechanism, ensuring that the drug payload is delivered predominantly to the intended cells.作者：K Bugatti·2023·被引用次数：12—This concept paper has the aim to give a short guide fordetermining the finest conjugation reactionto connect a specific drug to a particular peptide/ ...

While PDCs share similarities with ADCs, their unique characteristics position them as a distinct and highly promising therapeutic modalitynext generation of antibody-drug conjugates (ADCs)?. They represent a new frontier in targeted therapy and offer a compelling alternative for patients who may not respond to existing treatments. The ongoing research into peptide-drug conjugates in clinical trials and the increasing number of approved peptide-drug conjugates underscore their therapeutic significance and the confidence the scientific and medical communities have in their future. The prospect of developing peptide-drug conjugates: an emerging direction for the next generation of peptide therapeutics is incredibly exciting, offering hope for more effective and personalized medical interventionsPeptide-drug conjugates(PDCs) have the core advantages of enhanced cell permeability and improved drug selectivity..